These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

242 related articles for article (PubMed ID: 34312963)

  • 41. Multi-omics profiling of CSF from spinal muscular atrophy type 3 patients after nusinersen treatment: a 2-year follow-up multicenter retrospective study.
    Faravelli I; Gagliardi D; Abati E; Meneri M; Ongaro J; Magri F; Parente V; Petrozzi L; Ricci G; Farè F; Garrone G; Fontana M; Caruso D; Siciliano G; Comi GP; Govoni A; Corti S; Ottoboni L
    Cell Mol Life Sci; 2023 Aug; 80(8):241. PubMed ID: 37543540
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Cytochemical Characterization of Cerebrospinal Fluid Macrophage Inclusions in Pediatric Patients Receiving Intrathecal Nusinersen (SPINRAZA®) for Spinal Muscular Atrophy.
    Schafernak KT; Jacobsen JR; Hernandez D; Kaye RD; Perez SE
    Acta Cytol; 2022; 66(1):79-84. PubMed ID: 34515035
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neurochemical markers in CSF of adolescent and adult SMA patients undergoing nusinersen treatment.
    Wurster CD; Günther R; Steinacker P; Dreyhaupt J; Wollinsky K; Uzelac Z; Witzel S; Kocak T; Winter B; Koch JC; Lingor P; Petri S; Ludolph AC; Hermann A; Otto M
    Ther Adv Neurol Disord; 2019; 12():1756286419846058. PubMed ID: 31205491
    [TBL] [Abstract][Full Text] [Related]  

  • 44. A pediatric quantitative systems pharmacology model of neurofilament trafficking in spinal muscular atrophy treated with the antisense oligonucleotide nusinersen.
    Paris A; Bora P; Parolo S; MacCannell D; Monine M; van der Munnik N; Tong X; Eraly S; Berger Z; Graham D; Ferguson T; Domenici E; Nestorov I; Marchetti L
    CPT Pharmacometrics Syst Pharmacol; 2023 Feb; 12(2):196-206. PubMed ID: 36471456
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Intrathecal nusinersen treatment after ventriculo-peritoneal shunt placement: A case report focusing on the neurofilament light chain in cerebrospinal fluid.
    Tozawa T; Kasai T; Tatebe H; Shiomi K; Nishio H; Tokuda T; Chiyonobu T
    Brain Dev; 2020 Mar; 42(3):311-314. PubMed ID: 31889567
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Impact of Disease Severity and Disease-Modifying Therapies on Myostatin Levels in SMA Patients.
    Mackels L; Mariot V; Buscemi L; Servais L; Dumonceaux J
    Int J Mol Sci; 2024 Aug; 25(16):. PubMed ID: 39201450
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Nusinersen does not improve lung function in a cohort of children with spinal muscular atrophy - A single-center retrospective study.
    Heitschmidt L; Pichlmaier L; Eckerland M; Steindor M; Olivier M; Fuge I; Kölbel H; Hirtz R; Stehling F
    Eur J Paediatr Neurol; 2021 Mar; 31():88-91. PubMed ID: 33711791
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Nusinersen: A Treatment for Spinal Muscular Atrophy.
    Claborn MK; Stevens DL; Walker CK; Gildon BL
    Ann Pharmacother; 2019 Jan; 53(1):61-69. PubMed ID: 30008228
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Pharmacological and clinical profile of spinal muscular atrophy (SMA) therapeutic drug nusinersen (Spinraza
    Ohmura T; Saeki S; Ogiwara K; Tobita K; Ling Y; Torii S
    Nihon Yakurigaku Zasshi; 2018; 152(3):147-159. PubMed ID: 30185733
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Treatment expectations and patient-reported outcomes of nusinersen therapy in adult spinal muscular atrophy.
    Osmanovic A; Ranxha G; Kumpe M; Müschen L; Binz C; Wiehler F; Paracka L; Körner S; Kollewe K; Petri S; Schreiber-Katz O
    J Neurol; 2020 Aug; 267(8):2398-2407. PubMed ID: 32361837
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Nusinersen Modulates Proteomics Profiles of Cerebrospinal Fluid in Spinal Muscular Atrophy Type 1 Patients.
    Bianchi L; Sframeli M; Vantaggiato L; Vita GL; Ciranni A; Polito F; Oteri R; Gitto E; Di Giuseppe F; Angelucci S; Versaci A; Messina S; Vita G; Bini L; Aguennouz M
    Int J Mol Sci; 2021 Apr; 22(9):. PubMed ID: 33919289
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Cervical puncture to deliver nusinersen in patients with spinal muscular atrophy.
    Veerapandiyan A; Pal R; D'Ambrosio S; Young I; Eichinger K; Collins E; Westesson PL; Kwon J; Ciafaloni E
    Neurology; 2018 Aug; 91(7):e620-e624. PubMed ID: 30006410
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Combined treatment with the histone deacetylase inhibitor LBH589 and a splice-switch antisense oligonucleotide enhances SMN2 splicing and SMN expression in Spinal Muscular Atrophy cells.
    Pagliarini V; Guerra M; Di Rosa V; Compagnucci C; Sette C
    J Neurochem; 2020 Apr; 153(2):264-275. PubMed ID: 31811660
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Serum creatine kinase and creatinine in adult spinal muscular atrophy under nusinersen treatment.
    Freigang M; Wurster CD; Hagenacker T; Stolte B; Weiler M; Kamm C; Schreiber-Katz O; Osmanovic A; Petri S; Kowski A; Meyer T; Koch JC; Cordts I; Deschauer M; Lingor P; Aust E; Petzold D; Ludolph AC; Falkenburger B; Hermann A; Günther R
    Ann Clin Transl Neurol; 2021 May; 8(5):1049-1063. PubMed ID: 33792208
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Evaluation of Children with SMA Type 1 Under Treatment with Nusinersen within the Expanded Access Program in Germany.
    Pechmann A; Langer T; Schorling D; Stein S; Vogt S; Schara U; Kölbel H; Schwartz O; Hahn A; Giese K; Johannsen J; Denecke J; Weiß C; Theophil M; Kirschner J
    J Neuromuscul Dis; 2018; 5(2):135-143. PubMed ID: 29689734
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Response of plasma microRNAs to nusinersen treatment in patients with SMA.
    Zaharieva IT; Scoto M; Aragon-Gawinska K; Ridout D; Doreste B; Servais L; Muntoni F; Zhou H
    Ann Clin Transl Neurol; 2022 Jul; 9(7):1011-1026. PubMed ID: 35584175
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Population Pharmacokinetics of Nusinersen in the Cerebral Spinal Fluid and Plasma of Pediatric Patients With Spinal Muscular Atrophy Following Intrathecal Administrations.
    Luu KT; Norris DA; Gunawan R; Henry S; Geary R; Wang Y
    J Clin Pharmacol; 2017 Aug; 57(8):1031-1041. PubMed ID: 28369979
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Nusinersen: First Global Approval.
    Hoy SM
    Drugs; 2017 Mar; 77(4):473-479. PubMed ID: 28229309
    [TBL] [Abstract][Full Text] [Related]  

  • 59. NCALD Antisense Oligonucleotide Therapy in Addition to Nusinersen further Ameliorates Spinal Muscular Atrophy in Mice.
    Torres-Benito L; Schneider S; Rombo R; Ling KK; Grysko V; Upadhyay A; Kononenko NL; Rigo F; Bennett CF; Wirth B
    Am J Hum Genet; 2019 Jul; 105(1):221-230. PubMed ID: 31230718
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Scientific rationale for a higher dose of nusinersen.
    Finkel RS; Ryan MM; Pascual Pascual SI; Day JW; Mercuri E; De Vivo DC; Foster R; Montes J; Gurgel-Giannetti J; MacCannell D; Berger Z
    Ann Clin Transl Neurol; 2022 Jun; 9(6):819-829. PubMed ID: 35567345
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.